Key facts
- Mulsun Biotech’s last known valuation is $511.5M (Oct 2025).
- It has raised $77.7M; the latest was IPO in Jan 2026.
- Notable investors include Fosun Venture Capital Investment, China Merchants Group, Central SOEs Industrial Investment Fund for Poor Area, Gaoyun Capital, Hangzhou Shengchuang Jiye Private Equity Fund Management — 7 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for Mulsun Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Mulsun Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Mulsun Biotech
Developer and provider of industrialized silkworm rearing systems and silk protein-based products designed for year-round, high-efficiency, and sustainable production. The company enables textile, cosmetic, food, and packaging industries with stable, high-quality biomaterials through its integrated, technology-driven platform.
- Sector
- Materials and Resources
- HQ
- Shaoxing, China
- Founded
- 2015
- Employees
- 1,098
- Website
- lxm3s.com/
- Ownership
- Privately Held (backing)
Mulsun Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Mulsun Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Mulsun Biotech in its N-PORT filings yet. We sweep new filings monthly.